No more hand-me-down therapies for WM
Steven Treon, MD, PhD
NEW YORK, NY—Until recently, therapies to treat Waldenström’s macroglobulinemia (WM) have been borrowed from lymphoma, chronic lymphocytic leukemia, or myeloma.
But with our increased understanding of targeted signaling and the possibilities of novel therapies for this disease, WM is entering a new era, according to an expert.
Notify me when a comment is posted for this article
In This Section